About argenx
argenx is a company based in Ghent (Belgium) founded in 2008. argenx has raised $61.9 million across 11 funding rounds from investors including Crédit Agricole, Orbimed and PMV. The company has 355 employees as of December 31, 2022. argenx operates in a competitive market with competitors including Jazz Pharmaceuticals, Moderna, C4 Therapeutics, Forge Biologics and Erasca, among others.
- Headquarter Ghent, Belgium
- Employees 355 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
$1.41 B (USD)28as on Dec 31, 2022
-
Net Profit
-$527.76 M (USD)-32as on Dec 31, 2022
-
EBITDA
$211.72 M (USD)81as on Dec 31, 2022
-
Total Equity Funding
$61.9 M (USD)
in 11 rounds
-
Latest Funding Round
$700 M (USD), Post-IPO
Mar 24, 2022
-
Investors
Crédit Agricole
& 13 more
-
Employee Count
355
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of argenx
Unlock access to complete
Unlock access to complete
Leadership Team
81 people
Software Development Team
67 people
Senior Team
34 people
Product Management Team
24 people
Clinical Team
21 people
Finance and Accounting
18 people
Operations Team
17 people
Human Resources and Administration
13 people
Unlock access to complete
Funding Insights of argenx
argenx has successfully raised a total of $61.9M across 11 strategic funding rounds. The most recent funding activity was a Post-IPO round of $700 million completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in argenx
argenx has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include Crédit Agricole, Orbimed and PMV.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private debt funds are managed across multiple sectors.
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Early-stage life sciences & tech focused VC firm investing in geographies such as Europe
|
Locked | Locked | Locked |
Investor details for argenx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by argenx
Investment portfolio details for argenx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - argenx
Detailed financials for argenx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Argenx Comparisons
Peer comparison for argenx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of argenx
argenx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Moderna, C4 Therapeutics, Forge Biologics and Erasca, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of argenx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Argenx
Complete news archive for argenx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about argenx
argenx was founded in 2008 and raised its 1st funding round 1 year after it was founded.
argenx is headquartered in Ghent, Belgium. It is registered at Ghent, East Flanders, Belgium.
argenx is a funded company, having raised a total of $61.9M across 11 funding rounds to date.
As of Dec 31, 2022, the latest employee count at argenx is 355.
Annual revenue of argenx is $1.41B as on Dec 31, 2022.
Developer of antibody-based drugs to treat autoimmune diseases and cancer. The pipeline includes Oncology-ARGX-110, ARGX-111, ARGX-115, Autoimmunity ARGX-113, and ARGX-110. The proprietary technologies to identify the variable region from the llamas and introduces mutations in the constant region of the antibody for enhanced circulation in the system (NHance) and clearance post-therapy. The company has also developed a non-fucosylated antibody, which enhances antibody-dependent cytotoxicity.
argenx's top competitors include Moderna, Jazz Pharmaceuticals and C4 Therapeutics.
argenx has 14 investors. Key investors include Crédit Agricole, Orbimed, PMV, VIB, and European Union.